SAMR issues rare merger veto, orders 2019 Wuhan Yongtong–Huatai deal unwound
MLex Summary: Wuhan Yongtong Pharmaceutical’s completed 2019 acquisition of Shandong Beida Gaoke Huatai Pharmaceutical was blocked by China’s top merger control authority on July 22, marking only the fourth merger prohibition...To view the full article, register now.
Already a subscriber? Click here to view full article